Next Generation modRNA transfections are even Worse

A non-randomized Phase 1 clinical trialof a two dose self-amplifying modRNA transfection for COVID-19 was conducted among a handful of healthy adults in Uganda in 2022 (n = 42). Despite describing the vaxx as “safe” and “well tolerated” the study authors reported 39 grade 3 lab blood abnormalities following the booster after blood samples obtained from participants were analyzed. These consisted primarily of Neutropenia (abnormally low level of neutrophils), Lymphopenia (abnormally low levels of lymphocytes), and abnormally low blood platelet counts which occurred much more frequently in SARS-Coronavirus seropositive participants. Because one participant was hospitalized during the booster roll out only 41 received the booster meaning most participants in both seropositive arm and seronegative arm suffered one of these grade 3 lab abnormalities. They simply choose not to attribute them to the vaxx even though the frequency of grade 3 lab abnormalities increased 4x between the first dose (9) and booster (39) with no record of SARS-COV-2 infections occurring between doses.